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Background. Genetic polymorphisms of drug metabolizing enzymes involved in the detoxiﬁcation pathways of carcinogenic
substances may inﬂuence cancer risk. Methods. Case-control study that investigates the relationship between CYP1A1 Ile/Val, exon
4 mEH, and GSTM1 null genetic polymorphism and the risk of oral and pharyngeal cancer examining the interaction between
these genes, tobacco, and alcohol. 92 incident cases and 130 consecutive hospital-based controls have been included. Results.N o
signiﬁcant associations were found for any of the genotypes assessed. The estimated risk was slightly elevated in subjects with the
wild type of the mEH gene and the null GSTM1 genotype. For exon 4 mEH heterozygous polymorphism, the risk was slightly
lower for heavy smokers than for light smokers. The inverse association was observed for the GSTM1 null genotype. Conclusions.
The results suggest that exon 4 mEH and GSTM1 null polymorphisms might inﬂuence oral and pharyngeal cancer.
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1.Introduction
Oral and pharyngeal cancers represent an important prob-
lem worldwide. The incidence and prevalence rates for these
tumors are double in men than in women. Cancers of the
oral cavity rank as the eighth most common cancer among
men, being responsible for 3% of the cancers diagnosed in
this gender [1]. Mortality rates are substantially lower than
incidence rates. According to the World Health Organization
(WHO) data, the standardized mortality rate for 2002 was
2.2 deaths per 100000 population.
Tobaccoandalcoholarethemainriskfactorsfororaland
pharyngeal cancers. In USA and Europe, they are responsible
for 75–80% of these tumors [2, 3]. Epidemiologic studies
performed in all continents have found an increased risk
in smokers, which seems to rise with daily consumption
and duration [4–7] .T h e r ei sa l s os u ﬃcient evidence to
conclude that excessive consumption of alcoholic beverages
is associated with oral and pharyngeal cancers, causing in
some cases risks higher than those found for smokers [8–10].
The reason why some individuals develop cancer and
others do not can be attributed, at least partly, to variations
in genetic polymorphisms responsible for metabolizing car-
cinogenicsubstancesfoundintobaccoandalcohol.Although
many genes have been associated with metabolism of these
compounds, some with the highest rational of those being
involved are CYP1A1, mEH, and GSTM1.
The CYP1A1 gene belongs to the CYP1 subfamily and
encodes for the enzyme aryl hydrocarbon hydrolase, which
is involved in the activation of many polycyclic aromatic
hydrocarbons and aromatic amines [11] and is present in
oral tissue [12]. This enzyme is implicated in the metabolism2 Journal of Oncology
of benzo[a]pyrene, a potent tobacco carcinogen. Various
studies have shown that CYP1A1 catalyzes the initial con-
version of benzo[a]pyrene to 7,8 dihydrodiol-9,10-oxide
[13, 14]. Two CYP1A1 polymorphisms have been related to
diﬀerent tumors, including head and neck cancers. One of
these is a single-base substitution of adenine to guanine at
position 2455 in the heme-binding region of exon 7, which
inducesanaminoacidchangeinisoleucinetovalineatcodon
462, known as the Ile/Val or exon 7 polymorphism (Ile 462
Val) or CYP1A1∗2C. This mutation has also been referred
to as mutation m2. The Ile/Ile genotype corresponds to the
wild type, and Ile-Val and Val-Val to the heterozygous and
homozygous genotypes for the mutant allele, respectively
[15]. This mutation is rare in Caucasians, and is in complete
linkage disequilibrium with the CYP1A1 MspI mutation
(CYP1A1∗2B) [16].
T h em i c r o s o m a lf o r mo fe p o x i d eh y d r o l a s ei sp r i m a r i l y
associated with the metabolism of exogenous xenobiotic
compounds. Its interest in oral and pharyngeal cancers
comes from the fact that it has been detected in all
tissues including the aerodigestive tract and catalyzes the
hydrolosis of arene, alkene, and aliphatic epoxides from
polycyclic aromatic hydrocarbons and aromatic amines [17].
Enzymatically, mEH catalyzes the hydrolysis of epoxides to
trans-dihydrodiols[18,19].TwopolymorphismsinthemEH
gene have been reported [20, 21]. The ﬁrst polymorphism
is produced as a consequence of a substitution of C → T
within exon 3 of the gene and results in a substitution of
His to Tyr in amino acid position 113. This polymorphism
is known as the “slow allele” since in vitro studies show a
40–60% decrease in enzyme activity in comparison to the
wild type. This allele is also known as HYL∗2. In the second
polymorphism, G substitutes A in exon 4, leading to an
emplacement of histidine for arginine in the amino acid
position 139 (139Arg → His). This polymorphism is known
as the fast allele HYL∗3 since it produces a 25% increase in
enzyme activity in vitro. Tyr is the predominant amino acid
at the 113 position in Caucasian populations, and His is the
most predominant at position 139.
The glutathione S transferase (GST) comprises a family
of phase II detoxifying enzymes that catalyze a great number
of detoxiﬁcation reactions that take place between the
cytosolic glutathione and compounds containing an electro-
ﬁlic centre [22]. The GST substrates include acetaldehyde
and several polycyclic aromatic hydrocarbons found in
tobacco smoke. The GSTM1 is involved in the detoxiﬁcation
of benzo[a]pyrene-7,8-diol-9,10-oxide [23]. Metabolism of
this carcinogen involves a balance between the activation
steps mediated by the epoxide hydrolase and the cytochrome
system and the detoxiﬁcation steps, involving GSTM1, that
inhibit the activity of the DNA binding intermediates and
catalyze the conversion of the reactive electrophiles to
inactive, water-soluble conjugates that can be easily removed
[13].EventhoughfrequenciesofGSTM1nullgenotypesvary
among diﬀerent ethnic groups, in white Caucasians, it is
deleted in approximately 50% of the population [24–33].
In the present case-control study, we aimed to examine
the relationship between the CYP1A1 Ile/Val, exon 4mEH
(139Arg → His), and GSTM1 null genetic polymorphism
andtheriskoforalandpharyngealcancers,investigatingalso
the association with smoking, drinking, and the gene-gene
interactions.
2. Patients andMethods
2.1. Design, Subjects, and Settings. The present hospital-
based case-control study was conducted at the Santiago
de Compostela University Hospital Complex (Galicia, NW
Spain) between January 1996 and January 2000. Data was
collected on a total of 92 incident Caucasian male cases
withhistopathologicallyconﬁrmeddiagnosisofprimaryoral
or pharyngeal cancers. The study was restricted to newly
diagnosed patients over 20 years of age without a prior
history of cancer. For study purposes, tumors of the lip were
excluded.
A total of 130 consecutive controls were included from
patients attending the Hospital Complex Preoperative Unit
for nonsmoking- and nonalcohol-related trivial surgery. The
inclusion criterion for controls was absence of prior history
of cancer. Subjects under 20 years of age were excluded.
The types of surgical procedures controls were scheduled to
undergo mainly comprised inguinal hernias, cataracts, and
orthopedic surgery. Informed consent was obtained from all
study subjects prior to the interview and the extraction of
total blood. Only 1 case and 6 controls refused to participate
inthestudy.ThestudyprotocolwasapprovedbytheGalician
Ethical Research Committee.
2.2. Information Retrieval. All study subjects were inter-
viewed by a person purpose-trained to administer a struc-
tured questionnaire addressing various aspects of lifestyle,
with special emphasis on smoking habit, alcohol con-
sumption, occupation, and other activities related to the
development of oral and pharyngeal cancers. For cases, the
interview was done as soon as possible after cancer was
detected and always within 15 days from diagnosis. The
questionnaire used was previously applied to a group of
individuals fulﬁlling the characteristics of the subjects going
to be included and all questions with diﬃcult interpretation
were duly amended.
2.3. Laboratory Methods. After cases and controls were
identiﬁed, whole blood samples of 6mL were collected from
each subject in heparin-containing tubes. The samples were
stored at 4◦C and centrifuged at 2800rpm for at least 10
minutes within the next 24 hours. The three independent
fractions were isolated and stored at −84◦C until analysis.
DNA was extracted from the buﬀy coat of middle layer
containing monocytes. The cells were washed with TE (10x)
and centrifuged at 3000rpm during 10 minutes several times
until they were cleaned. The pellet was then treated with lysis
buﬀerandproteinaseKin1%SDSprevioustotheextraction
of DNA with phenol-chloroform and ethanol precipitation
similarly as previously described [34]. The DNA was precip-
itated in the presence of high concentrations of ammonium
acetate (to further purify the DNA) and resuspended in TE
to approximately 300μg/mL. The genotyping assays wereJournal of Oncology 3
performed at the Molecular Medicine Unit of the Santiago
de Compostela University Hospital Complex.
Genotyping for GSTM1 was carried out in the whole
sample using a modiﬁed PCR method described previously
[35]. Reactions were carried out in a ﬁnal volume of 12.5μL
containing 20mM Tris-HCl (PH 8.4), 50mM KCl, 3mM
MgCl2,0 . 2 5μMo fe a c hG S T M 1p r i m e r ,0 . 2 5μMo fe a c hβ-
globin primer (internal control), 1U Taq DNA polymerase
(Promega), 2μM each dNTPs, and 600–900ng of DNA. The
GSTM1 primers were 5 -GAACTCCCTGAAAAGCTAAGC
and 5 -GTTGGGCTCAAATATACGGTGG. A negative con-
trol was included in all batches. The PCR conditions were
94◦ for 3 minutes, followed by 35 cycles of 94◦Cf o r3 0
seconds,58◦Cfor30seconds,72◦Cfor45seconds,andaﬁnal
extension of 72◦Cf o r7m i n u t e s .
To analyse the exon 4mEH polymorphism (EH139 arg), a
357-bpfragmentcontainingthepolymorphicsitewasampli-
ﬁed [36]. The PCR was performed in all subjects using the
sense primer 5 -GGGGTGCCAGAGCCTGACCGT-3  and
the antisense primer 5 -AACACCGGGCCCACCCTTGGC-
3  (Sigma-Genosys). The PCR cycling conditions were 95◦C
for 2 minutes, followed by 35 cycles at 95◦Cf o r3 0
seconds, 60◦C for 30 seconds, 72◦C for 30 seconds, with a
ﬁnal step at 72◦C for 7 minutes. After PCR ampliﬁcation,
10μL of the PCR product was digested overnight at 37◦C
with 10U of RsaI (Invitrogen). The wild-type genotype
(AA) produced 295-bp and 62-bp bands, the heterozygous
genotype (AG) yielded 295-bp, 174-bp, 121-bp, 62-bp;
and the rare allele (GG) gave 174-bp, 121-bp, and 62-bp
bands.
The Ile-Val polymorphism was analysed in only 158
of the 222 individuals included using an allele-speciﬁc
oligonucleotide-PCR procedure previously described by
Hayashi et al. [16]. In the same reaction mix, two primers
with diﬀerent terminal bases (1A1A or 1A1G), which con-
tained the polymorphic site at the 3 end, were added (1A1G :
5 -GAACTGCCACTTCAGCTGTCT-3  and 1A1A : 5 -AAG-
ACCTCCCAGCGGGCAAT-3 )inconjunctionwithanother
strand of primer (1A1.1 : 5 -GAACTGCCACTTCAGCTG-
TCT-3 ). Two ampliﬁcation reactions were necessary for
each one of the subjects analysed, one with the primers
1A1.1/1A1A which recognize the Ile462 allele and another
with the primers 1A1.1/1A1G which recognize the Val462
allele. PCR was carried out at 30 cycles under the following
conditions: 30 seconds at 95◦ for denaturing, 1 minute at
60◦C for primer annealing, and 1 minute at 72◦Cf o rp r i m e r
extension.
All the products were electrophoresed on a 2% agarose
gel stained with ethidium bromide and visualized under UV
light. To test for eventual contamination, negative controls
were introduced in each run.
2.4. Statistical Analysis. Logistic regression was employed
to analyse the eﬀect of each of the genes studied. The
wild type gene was considered as the reference category
for each gene in each analysis. All the regressions were
adjusted for age, tobacco consumption in pack-years, and
alcohol consumption in grams/week. For analyzing the eﬀect
of the diﬀerent polymorphisms across diﬀerent categories
of tobacco and alcohol consumption, the cutpoint was
established on the median creating two categories, low and
high consumption in order to achieve a higher statistical
power. In all analyses, the dependent variable was the status
of case or control and the risks were expressed as ORs with
CI 95%. All the analyses were performed with SPSS 11.5
statistical package.
3. Results
The study population covered a total of 222 subjects,
comprising 92 cases and 130 controls. A description of the
sample characteristics is presented in Table 1. The mean age
of the controls (59.4 years; CI 95% 57–61.8) was slightly
higher than that of cases (55 years; CI 95% 52.7–57.3).
The 57.6% of the tumors were located in the oral cavity
(tongue 27, oral ﬂoor 7, palate 6, and other parts 12) and
96.7% were squamous cell carcinomas. Smoking and alcohol
consumption were more frequent among cancer cases than
controls. A percentage of 98% of the cases were smokers and
46.7% of these (n = 43) were considered as heavy drinkers
(more than six glasses of wine/beers or two liquors a day),
whilst in the control group 62% of the individuals smoked
and 10.8% (n = 14) were heavy drinkers.
The frequency of GSTM1 null genotype was 51.1%
among oral and pharyngeal cancer patients and 47.7%
among controls. The exon 4mEH (139Arg → His) het-
erozygous polymorphism (His/Arg) was present in 31.5% of
the control group and in 27.2% of the case group. Only 4
subjects (4.3%) in the case group and 1 subject in the control
group (0.8%) presented homozygous mutations. There were
no diﬀerences in the frequency of mutations for the CYP1A1
exon 7 polymorphism. The mutant alleles (Ile/Val, Val/Val)
were observed in only 2 cases (3%) and 2 controls (2.2%).
Table 2 shows the odds ratio estimates for combined
oral and pharyngeal cancers associated with the GSTM1,
CYP1A1, and exon 4mEH polymorphisms. To determine
the eﬀect of these polymorphisms on diﬀerent cancer sites,
oral cavity and pharyngeal tumors were evaluated separately.
No statistically signiﬁcant eﬀect was observed for any of the
polymorphisms studied for any of the anatomic subtypes.
The limited number of subjects with mutant CYP1A1 alleles
did not allow for a calculation of the OR for oral cavity
tumors.
To assess dose-response relationship, we have calcu-
lated pack-years of smoking (1 pack (20 cigarettes/day) ×
years of smoking). Smokers were classiﬁed as non-to-
light/moderatesmokers(≤35pack-years)andheavysmokers
(>35 pack-years). Non smokers were analysed together
with light/moderate smokers because there were only 2
nonsmokers among the cases and this did not allow for a
separate analysis. The odds ratios associated with tobacco
consumption by the diﬀerent genotypes analysed are shown
in Table 3. This analysis was not performed for CYP1A1 due
to the limited number of patients with mutated alleles and
thesamehappenedforalcoholconsumption.FortheHis/Arg
genotype of exon 4mEH, it could be observed that the risk
was slightly lower for heavy smokers (OR 0.68; 95% CI 0.25–
1.86)thanforlightsmokers(OR1.08;95%CI0.37–3.13)but4 Journal of Oncology
Table 1: Description of the study individuals.
Variable considered Cases Controls
Age (mean, IC95%) 55.0 (52.7–57.3) 59.4 (57.0–61.8)
Cancer location
Oral 53 (57.6%)
Pharyngeal 39 (42.4%)
Cigarette smoking
Never smoker 2 (2.2%) 49 (37.7%)
Former smoker 17 (18.5%) 42 (32.3%)
Current smoker 73 (79.3%) 39 (30%)
Tobacco consumption (pack-years)
Percentil 25 33.0 0
Percentil 50 46.5 9.9
Percentil 75 67.5 43.8
Drinking habit
No alcohol drinking 2 (2.2%) 20 (15.4%)
Light drinker (≤2 glasses of wine/beers or 2 licors a day) (0–280gm/week) 6 (6.5%) 50 (38.5%)
Moderate drinkers (3–6 drinks/day) (281–840g/week) 41 (44.6%) 46 (35.4%)
Heavy drinkers (>6 drinks/day) (>840gm/week) 43 (46.7%) 14 (10.8%)
Alcohol consumption gm/week
Percentil 25 290 70
Percentil 50 560 145
Percentil 75 840 300
CYP1A1
Wild type (Ile/Ile) 64 (97%) 90 (97.8%)
Mutation (Ile/Val, Val/Val) 2 (3%) 2 (2.2%)
mEH (139Arg → His)
Arg/Arg 63 (68.5%) 88 (67.7%)
Arg/His 25 (27.2%) 41 (31.5%)
His/His 4 (4.3%) 1 (0.8%)
GSTM1
Present (GSTM1 +) 45 (48.9%) 68 (52.3%)
Absent (GSTM1 −) 47 (51.1%) 62 (47.7%)
Total 92 130
the associations were not signiﬁcant for any of the categories
oftobaccoconsumption.TheGSTM1nullgenotyperevealed
an inverse pattern, showing an OR of 0.88 (95% CI 0.34–
2.34)forlightsmokersandanORof1.40(95%CI0.57–3.43)
for heavy smokers.
To examine the interaction between these genotypes and
the drinking status, we carried out a second stratiﬁcation
analysis. Two categories of alcohol consumption were estab-
lished. Those that consumed 280gm/week of alcohol or less
(≤2 glasses of wine/beers or 2 liquors a day) were considered
as light drinkers, and those that exceeded those values as
heavy drinkers. Once again, due to the low number of
nondrinkers among the cases (n = 2), these subjects were
analysed in combination with light drinkers. The risks for
the two diﬀerent categories of alcohol consumption, light
and heavy drinkers, are displayed in Table 4. There seems
to be a very slight nonsigniﬁcant negative association for
the His/Arg genotype of exon 4mEH for both categories
of alcohol consumption. The GSTM1 gene has a diﬀerent
eﬀect, with its absence posing a slightly higher association
for light drinkers (OR 1.97; 95% CI 0.73–5.35) than for
moderate/heavy drinkers (OR 0.69; 95% CI 0.28–1.72).
The interaction between mEH and GSTM1 genes is
shown in Table 5. No signiﬁcant eﬀect was detected for the
interaction although the estimated risk was higher for those
subjects with the wild-type mEH gene and the null GSTM1
genotype (OR 1.45; 95% CI 0.66–3.17). There was no any
apparenteﬀectwhenbothgenesweremutatedorabsent(OR
1.07; 95% CI 0.39–2.92).
4. Discussion
Even though previous studies have been undertaken to
examine the association between CYP1A1 Ile/Val, mEH,
and GSTM1 null polymorphisms, as well as oral and
pharyngeal cancers, few investigated the modiﬁcation ofJournal of Oncology 5
Table 2: Risks for oral and pharyngeal cancers associated with polymorphisms in genes CYP1A1, mEH, and GSTM1.
Gene Cases Controls OR crude (CI 95%)∗ OR adjusted (CI 95%)+
All cancers
CYP1A1
No mutated 1.00 1.00
Mutated 0.72 (0.10–5.28) 1.68 (0.18–15.70)
mEH (139His → Arg)
His/His 1.00 1.00
His/Arg 0.95 (0.52–1.75) 0.81 (0.38–1.71)
Arg/arg 4.30 (0.46–40.07) 4.45 (0.39–50.45)
GSTM1
Present 1.00 1.00
Absent 1.16 (0.73–1.99) 1.25 (0.65–2.40)
Oral cancer
CYP1A1
No mutated 53 64 (97%) 1.00 1.00
Mutated 0 2 (3%) — —
mEH (139His → Arg)
His/His 39 (73,6%) 88 (67,7%) 1.00 1.00
His/Arg 12 (22,6%) 41 (31,5%) 0.74 (0.34–1.58) 0.54 (0.21–1.41)
Arg/arg 2 (3,8%) 1 (0,8%) 3.44 (0.29–40.16) 4.32 (0.32–58.63)
GSTM1
Present 26 (49,1%) 68 (52,3%) 1.00 1.00
Absent 27 (50,9%) 62 (47,7%) 1.14 (0.60–2.19) 1.20 (0.56–2.18)
Pharyngeal cancer
CYP1A1
No mutated 37 (94,9%) 64 (97%) 1.00 1.00
Mutated 2 (5,1%) 2 (3%) 1.74 (0.23–12.92) 4.06 (0.43–38.24)
mEH (139His → Arg)
His/His 24 (61,5%) 88 (67,7%) 1.00 1.00
His/Arg 13 (33,3%) 41 (31,5%) 1.27 (0.58–2.80) 1.07 (0.42–2.71)
Arg/arg 2 (5,2%) 1 (0,8%) 5.58 (0.47–66.10) 5.74 (0.34–97.71)
GSTM1
Present 19 (48,7%) 68 (52,3%) 1.00 1.00
Absent 20 (51,3%) 62 (47,7%) 1.20 (0.58–2.48) 1.44 (0.61–3.37)
∗Adjusted for age.
+Adjusted for age, smoking, and alcohol intake.
risk associated with tobacco and alcohol consumption, and
to our knowledge, this is the ﬁrst to analyse the gene-
gene interactions between these polymorphisms. Our results
support the view that there is no signiﬁcant association for
any of these polymorphisms in Caucasians but our data
suggest that exon 4mEH (139Arg → His) and GSTM1 null
polymorphism might modify the risk related to tobacco and
alcohol consumption.
We observed that the exon mEH polymorphism
139Arg → His was mutated in a very similar proportion
in cases and controls and the frequencies found (32,3%
in controls versus 31,5% in cases) were consistent with
the results of the previous investigations that assessed the
association between this polymorphism in head and neck
tumors in both sexes [32, 37–41]. In these studies, mutated
alleles were present in 29.7–39.8% of the control population
and in 28.9–39% of the cancer patients. In the present
analysis,theestimatedriskswerenotsigniﬁcantforanyofthe
tobacco or alcohol consumption levels but the results were in
agreement with those of Wenghoefer et al. [37] that showed
that the heterozygous allele (His/Arg) of exon 4mEH could
modulate the risk of head and neck cancer in smokers (OR
0.57; CI 95% 0.34–0.95). In our study, the risk was lower in
heavy smokers (OR 0.68; 95% CI 0.25–1.86) than in light
smokers (OR 1.08; 95% CI 0.37–3.13) but not signiﬁcant,
maybe inﬂuenced by the small sample size.
Enzymaticaly, mEH catalyzes the hydrolysis of arene,
alkene, and aliphatic epoxides from polycyclic aromatic
hydrocarbons and aromatic amines to trans-dihydrodiols
[19]. This reaction is usually regarded as a detoxifying path-
way because the majority of metabolites produced are less
reactive and can be easily excreted, but, in some instances,6 Journal of Oncology
Table 3: Risks for the diﬀerent polymorphisms broken down by smoking categories.
Genetic polymorphism Cases Controls OR crude OR adjusted
Light/moderate smokers (≤35 pack-years)
CYP1A1
No mutated 28 41 1.00 1.00
Mutated 1 2 0.76 (0.06–8.90) 1.12 (0.09–13.94)
mEH (139His → Arg)
His/His 20 58 1.00 1,00
His/Arg 8 24 1.06 (0.40–2.78) 1.08 (0.37–3.13)
Arg/arg 1 1 1.91 (0.11–33.10) 2.82 (0.15–52.41)
GSTM1
Present 17 43 1.00 1.00
Absent 12 40 0.74 (0.31–1.76) 0.88 (0.34–2.34)
Heavy smokers (>35 pack-years)
CYP1A1
No mutated 23 62 1.00 1.00
Mutated 0 1 — —
mEH (139His → Arg)
His/His 43 30 1.00 1.00
His/Arg 17 17 0.94 (0.39–2.26) 0.68 (0.25–1.86)
Arg/arg 3 0 — —
GSTM1
Present 28 25 1.00 1.00
Absent 35 22 1.50 (0.67–1.33) 1.40 (0.57–3.43)
Table 4: Risks for the diﬀerent polymorphisms broken down by alcohol intake.
Genetic polymorphism Cases Controls OR crude OR adjusted
Light drinkers (≤280gm alcohol/week)
CYP1A1
No mutated 23 43 1.00 1.00
Mutated 0 2 — —
mEH (139His → Arg)
His/His 18 64 1.00 1.00
His/Arg 5 31 0.57 (0.19–1.72) 0.71 (0.22–2.24)
Arg/arg 0 1 — —
GSTM1
Present 10 52 1.00 1.00
Absent 13 44 1.55 (0.62–3.88) 1.97 (0.73–5.35)
Moderate/heavy drinkers (>280gm alcohol/week)
CYP1A1
No mutated 67 21 1.00 1.00
Mutated 2 0 — —
mEH (139His → Arg)
His/His 45 24 1.00 1.00
His/Arg 20 10 1.28 (0.50–3.31) 0.83 (0.30–2.30)
Arg/arg 4 0 — —
GSTM1
Present 35 16 1.00 1.00
Absent 34 18 0.79 (0.34–1.86) 0.69 (0.28–1.72)Journal of Oncology 7
Table 5: Combination of polymorphisms mEH and GSTM1 and risk of oropharyngeal cancer.
Combination of genetic polymorphisms Cases Controls OR crude OR adjusted
mEH (Arg/Arg)/GSTM1 present 31 48 1.00 1.00
mEH (Arg/Arg)/GSTM1 absent 32 40 1.22 (0.63–2.36) 1.45 (0.66–3.17)
mEH mutated/GSTM1 present 14 20 1.15 (0.50–2.65) 1,19 (0.43–3.27)
mEH mutated/GSTM1 absent 15 22 1.18 (0.52–2.66) 1.07 (0.39–2.92).
these initial trans-dihydrodiol metabolites can be further
activated by subsequent P450 catalysis to form highly car-
cinogenic electroﬁlic intermediates that can bind covalently
to DNA. Such is the case of the 7,8-diol-9,10-epoxide, which
is more carcinogenic than the other benzo[a]pyrene diol
epoxide formed [42]. Whilst the results of some studies,
including the present one, are compatible with the fact that
a high or intermediate activity might exert a protective eﬀect
in subjects exposed to tobacco products [39, 43, 44], others
carried out in various aerodigestive tract cancers ﬁnd no
association or a signiﬁcantly higher risk for smokers with
the exon 4mEH variant allele [32, 36, 38, 39]; reasons for
these inconsistencies are unclear. It could be argued that
high activity should be assessed taking into account both
the exon 3 and exon 4mEH polymorphisms. Some authors
predicted mEH activity as low, intermediate, or high based
on the presence or absence of the two polymorphisms but
the results are also contradictory [37, 38, 40, 41, 45, 46].
The study undertaken by Wenghoefer et al. [37]f o u n da n
association for the single genotypes in head and neck cancers
but not the combination genotypes, raising uncertainties
in categorizing enzymes. Given the dual role of mEH on
the bioactivation/detoxiﬁcation of carcinogens, it is highly
probable that other polymorphisms might inﬂuence the
formation of carcinogenic metabolites and that gene-gene
interactions might exist. In this investigation, we did not
ﬁnd a signiﬁcant interaction between the GSTM1 and exon
4mEH polymorphism.
The frequency of the GSTM1 null allele polymorphisms
in oral and pharyngeal cancers has been reported to vary
greatly depending on the geographical regions [47, 48].
Whilst in Europe and USA the frequencies reported in
controlpopulationsrangefromaround49–55.6%[24–32]in
Asian and South American countries, this allele is frequently
present in less than 49% of the control subjects [49–60]. In
the present study, 47.7% of the control population presented
the GSTM1 null polymorphism. This is slightly lower than
the values found in other Caucasian studies and could
be partly due to the fact that only males were included.
Our study, like other previous reports on Caucasians [24–
26, 28–32], failed to ﬁnd a signiﬁcant association between
the GSTM1 null polymorphism and oral and pharyngeal
cancers. Several studies undertaken in Asian populations
showed contradictory results [49, 56–60]. In a very recent
meta- and pooled analysis, it was observed that the GSTM1
null polymorphism was signiﬁcantly associated with risk
in Asian and African-American populations in the meta-
(OR 1.5; 95% CI 1.3–1.8) and pooled (adjusted OR 2.4,
95% CI 1.1–5.5) analysis, respectively, but not in Caucasians
[48]. This discrepancy might be attributed to diﬀerences in
lifestyle, environmental risk factors, and variations in the
activity of other metabolizing enzymes, which often displays
genetic polymorphisms that might diﬀer in Caucasians and
in other ethnic groups [11, 41, 59, 61].
We did not ﬁnd a signiﬁcant interaction between the
GSTM1 null polymorphism and tobacco smoking, but we
did observe that the risk was slightly higher in heavy
smokers than in light/moderate smokers. To verify that these
diﬀerences were not due to the fact that nonsmokers were
analysed together with light/moderate smokers, we carried
out a separate analysis leaving out these subjects and found
that the variations in the odds ratios were minimum (data
not shown). It has been hypothesised that lack of GSTM1
enzyme activity increases cancer susceptibility as a result of a
decreasedabilitytodetoxifyreactiveintermediatesoftobacco
carcinogens such as benzo[a]pyrene-7,8-diol epoxide, the
activated form of benzo[a]pyrene [22] but the results of
previous studies undertaken in oral and pharyngeal cancers
are inconsistent [26, 54, 56, 57]. Some authors ﬁnd a lower
diﬀerence in risk among the genotypes at high dose levels
and suggest a dose-response relationship of the enzymatic
reaction [48, 57]. In the present study, the relationship
between tobacco exposure and these polymorphisms is
diﬃcult to assess because there were only 2 nonsmokers
among the cases and 6 subjects that smoked for less than 20
years, forcing us to create a category that was light/moderate
smokers. Studies with larger number of patients are needed
to properly assess this dose response relationship taking
into account that ethnic and geographical diﬀerences might
exist due to the diﬀerent forms of tobacco consumption
and diet intake. In Asian and South American countries,
tobacco is usually smoked as “bidis” and the carcinogenic
substances found in this form of preparation are diﬀerent to
that in cigarettes, implying that other enzymes diﬀerent than
GSTM1 and CYP1A1 might be involved in the detoxiﬁcation
[28].
Our study suggests that the eﬀect of the GSTM1 null
polymorphism is more noticeable among light drinkers,
although this association was nonsigniﬁcant. This relation-
ship was maintained when we took out the nondrinkers
from the analysis (data not shown). This diﬀerential eﬀect
could be explained by the fact that the GSTM1 isoenzyme,
together with the alcohol dehydrogenase, is involved in the
oxidation of ethanol to acetaldehyde [30]. Even though the
exact mechanisms by which ethanol may exert an inﬂuence
in oral cancer is still unknown, it has been suggested that
acetaldehyde, a known carcinogenic agent, [62]c o u l db e
responsible for some DNA changes that could lead to cancer
[63]. Individuals with a null GSTM1 and high drinkers
would not convert ethanol in acetaldehyde and then the8 Journal of Oncology
absence of the gene would confer them a protective eﬀect
for oropharyngeal cancer. Another explanation for these
ﬁnding could be that ethanol increases the permeability of
tobacco carcinogens, such as nitrosonornicotine, across the
oral membrane when it is present at low concentrations. At
concentrations higher than 50%, no further permeabiliza-
tion is noted, probably due to the ﬁxative eﬀect of ethanol
on the mucosa [64]. It should be highlighted that the alcohol
consumptionintheGalicianpopulationisveryhigh,asother
studies have reported [65], and this is a limitation that does
not allow for a proper analysis of the interaction.
Even though the CYP1A1 mutation has been shown to
increase microsomal activity for converting procarcinogens,
including PAH aromatic amines, the results of various
reports on smoking-related cancers are inconsistent [11, 32,
47, 66–70]. It has been suggested that the DNA damage
may depend on the link of CYP1A1 to other polymorphisms
that can aﬀect the CYP1A1 transcription levels, such as
polymorphisms for promoter genes, AHR (Ah receptor)
genes, or metabolic genes such as GSTM1 [69, 70]. In our
study, only 4 of the analysed subjects showed an Ile/Val
mutation. Although these frequencies are in accordance with
those found by Hahn et al. in a Caucasian population
[25], it made it impossible to draw any conclusion for
this polymorphism. Conﬁdence intervals obtained were very
wide and the distribution of this polymorphism was very
similar between cases and controls. In any case, neither the
previous meta- and pooled analysis on CYP1A1 and risk
of head and neck cancer [47] nor the recently published
meta and pooled analysis on oral and pharyngeal cancer
found a signiﬁcant association between CYP1A1 (Ile/Val)
polymorphism and oral and pharyngeal cancer [48].
This paper has several limitations. The main one is the
smallsamplesizeincluded.Thisisespeciallyimportantwhen
analyzing polymorphisms that have a very low frequency in
the population, such as CYP1A1 Ile/Val, but also limits the
power to identify gene-environmental and gene-gene inter-
actions in any polymorphisms investigated. Nevertheless, it
has to be taken into account that for cancers with a low
incidence such as oral and pharyngeal ones, 92 cases can
be a relatively good number. Another limitation could be
the fact that our study was hospital-based and this could
result in selection bias. Even though it has been suggested
that studies with hospital controls can provide lower risk
estimates, since diseases of controls could be associated with
the polymorphisms under study, previous meta- and pooled
analysisthatassessedthesepolymorphismsonheadandneck
cancers found no diﬀerences for hospital-based studies in
relation to population-based studies [47, 66]. The fact that
not all the sample was analysed for CYP1A1 polymorphisms
limited the power to detect a signiﬁcant risk.
The present study has also some advantages. One of
them is that the participation of cases and controls was very
high. All the cases belonged to the same catchment area,
which has a unique reference hospital, and were collected
consecutively,makingthemrepresentativeofthecasesinthat
area. The controls also belonged to the same area and did not
have any symptom or disease related to alcohol or tobacco
consumption. Another advantage is the fact that the genes
analysed here were of phase I and phase II, which adds value
to the results obtained. When studying susceptibility genes
in many occasions, both types of genes are not studied and
individuals can have susceptibility in type I compensated
with the activity of the other type such as it was shown in
Park et al. investigation [29].
As a conclusion, it seems that even though none of the
three genotypes analysed have a signiﬁcant association with
the risk of oral and pharyngeal cancer in this population,
the risks of tobacco and alcohol consumption might be
modiﬁed by GSTM1 null and exon 4mEH polymorphisms.
The small number of nonsmoking and nondrinking subjects
in our population limited our analysis, so we propose that
further studies are carried out to clarify this question.
Even though we found no signiﬁcant interaction between
the GSTM1null genotype and the exon 4mEH genotype,
the GSTM1 absence did show a slight rise in risk so
this should also be investigated taking into account other
polymorphisms including the CYP1A1.
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